ANALYSIS OF HIV PROTECTIVE IMMUNITY

艾滋病疫苗和治疗发展的一个主要障碍是 对什么构成对艾滋病毒-1的保护性免疫的理解不全面。 为了了解体液免疫在预防艾滋病毒中的作用 感染，我们正在研究HIV-1的抗体中和。两者都使用 我们正在分析多克隆和单克隆抗体的敏感性 各种初级和实验室病毒分离株的模式。 中和抗体活性在自体和 异源病毒分离株的流行中和研究 抵抗。我们发现，中和艾滋病毒的能力并不取决于 不仅取决于个人的抗体谱系，而且还取决于表型 在患者体内生长的HIV病毒。这些HIV中和 抗性和敏感性模式正在使用以下方法进行基因图谱绘制 用患者病毒包膜氨基酸构建的嵌合HIV毒株 被替换到已知病毒背景中的酸序列，然后进行测试 以提高抗体敏感性。用单抗和分型进行分析 特异性抗血清应为患者分离株的免疫分型提供方法 并评估临床上对候选艾滋病毒疫苗的体液反应 审判。

A major obstacle to AIDS vaccine and therapeutic development is the incomplete understanding of what constitutes protective immunity to HIV-1. In order to understand the role of humoral immunity in preventing HIV infection, we are studying antibody neutralization of HIV-1. Using both polyclonal and monoclonal antibodies we are analyzing the sensitivity patterns of a variety of primary and laboratory virus isolates. Neutralizing antibody activity is being measured both on autologous and heterologous virus isolates to investigate the prevalence neutralization resistance. We are finding that the ability to neutralize HIV depends not only on the antibody repertoire of an individual but also on the phenotype of HIV which is growing in the patient. These HIV neutralization resistance and susceptibility patterns are being genetically mapped using chimeric HIV strains constructed using a patient's viral envelope amino acid sequence substituted into a known viral background and then tested for antibody sensitivity. Assays with monoclonal antibodies and type specific antisera should provide methods to immunotype patient isolates and to evaluate humoral responses to HIV vaccine candidates in clinical trials.